Virpax appointed three independent directors: Eric Floyd, PhD, Jerrold Sendrow, CFP and Thani Jambulingam, PhD, at their Annual General Meeting of the Shareholders.
Virpax Licenses Technology from Yissum Research Development Company of the Hebrew University of Jerusalem.
Virpax is presenting two posters in the MHSRS Pain Management for the Future Fight on Wednesday, August 21, 2019.
Michèle C. Linde has been appointed as the Company’s Executive Vice President, General Counsel and Corporate Secretary.
Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2019 Military Health System Research Symposium (MHSRS) being held August 19-22, 2019, at the Gaylord Palms Resort and Convention Center in Kissimmee, FL.
The Chairman and CEO of Virpax® Pharmaceuticals, Anthony P. Mack, presented at the ThinkEquity Conference on May 2nd. If you missed it, or want to re-listen, you can access the archived webcast here.
Anthony P. Mack, Chairman and CEO of Virpax will be presenting at the ThinkEquity Conference at 12:30 p.m. ET on Thursday, May 2, 2019.
Virpax Pharmaceuticals has partnered with Naomerics Ltd. to develop a non-opioid Molecular Envelope Technology (MET) intranasal formulation for the management of chronic pain.
Virpax Pharmaceuticals completed a successful pre-IND Meeting with the US Food and Drug Administration.
This article from Life Science Leader magazine features the views of top executives, including Virpax's CEO Anthony Mack, on how the life sciences industry business model meets public health obligations.
Under FDA guidance, Virpax Pharmaceuticals plans to finalize IND and prepare for Phase 1 human study.
Virpax Pharmaceuticals has licensed MedPharm’s topical spray technology to develop a transdermal patch for non-opioid pain management products.
MedPharm Licenses Its MedSpray® ‘Patch-in-a-Can’ Technology to Virpax Pharmaceuticals for Non-Opioid Pain Management Products.
Virpax Pharmaceuticals signs technology license agreement with LipoCure to develop pain management products using its liposome drug delivery products.
Virpax Pharmaceuticals has licensed MedPharm's "Patch-in-a-Can" MedSpray® Technology to develop non-opioid pain management products.
Abstracts featuring DSF100 and NES100 will be presented at this year's exhibition.
Virpax has exclusive global rights to use Nanomerics’ nanotechnology for the delivery of a metabolically labile intranasal peptide for the management of Post-Traumatic Stress Disorder (PTSD).
Michèle C. Linde has been promoted to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary.